1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea

This compound is a synthetic small molecule inhibitor with the IUPAC name 1-{4-[4-Amino–6-(4-methoxyphenyl)furo[2,3-d]pyrimidin–5–yl]phenyl}–3–[2-fluoro–5-(trifluoromethyl)phenyl]urea. It is primarily studied as an experimental agent in medicinal chemistry for its potential to inhibit receptor tyrosine kinases involved in angiogenesis and tumor growth. Notably, it has been identified as an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2/KDR/Flk1), and may also interact with the angiopoietin receptor TIE2. The mechanism of action involves blocking these receptors' kinase activity, thereby inhibiting downstream signaling pathways that promote cell proliferation and migration—key processes in cancer progression and neovascularization. There are no approved clinical indications or marketed products containing this compound; it remains at the preclinical or early research stage.[1][3][6]

Other names

1-[4-[4-amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-y]phenyl]-3-[2-fluoro–5-(trifluoromethyl)phenyl]urea hydrochloride501693–25–0